1. Home
  2. GVA vs ACAD Comparison

GVA vs ACAD Comparison

Compare GVA & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Granite Construction Incorporated

GVA

Granite Construction Incorporated

HOLD

Current Price

$116.14

Market Cap

4.5B

Sector

Industrials

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$27.23

Market Cap

4.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GVA
ACAD
Founded
1922
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
4.6B
IPO Year
1990
2004

Fundamental Metrics

Financial Performance
Metric
GVA
ACAD
Price
$116.14
$27.23
Analyst Decision
Hold
Buy
Analyst Count
3
22
Target Price
$105.00
$29.05
AVG Volume (30 Days)
634.1K
1.4M
Earning Date
11-06-2025
11-05-2025
Dividend Yield
0.45%
N/A
EPS Growth
68.53
98.53
EPS
3.67
1.54
Revenue
$4,236,312,000.00
$1,047,118,000.00
Revenue This Year
$11.29
$15.16
Revenue Next Year
$10.61
$11.42
P/E Ratio
$31.38
$17.62
Revenue Growth
6.87
12.69
52 Week Low
$69.08
$13.40
52 Week High
$115.88
$27.73

Technical Indicators

Market Signals
Indicator
GVA
ACAD
Relative Strength Index (RSI) 79.75 70.21
Support Level $107.77 $26.38
Resistance Level $110.31 $27.73
Average True Range (ATR) 2.43 0.81
MACD 1.04 0.11
Stochastic Oscillator 89.23 87.25

Price Performance

Historical Comparison
GVA
ACAD

About GVA Granite Construction Incorporated

Granite Construction Inc engages in the construction and development of various infrastructure projects on behalf of public and private clients in the United States. It focuses on heavy civil infrastructure projects, including roads, highways, transit facilities, airports, bridges, and other infrastructure projects. In addition, the company performs site preparation and infrastructure services for residential development, energy development, and other facilities. The majority of revenue is derived from the company's Construction operating segment, with the remainder derived from its Materials segment.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Share on Social Networks: